Anemia and Adverse Outcomes in Pregnancy: Subgroup analysis of the CLIP Cluster-Randomized Trial in India

Jeffrey N. Bone

University of British Columbia

Mrutyunjaya Bellad

KLE Academy of Higher Education and Research's J N Medical College

Shivaprasad Goudar

KLE Academy of Higher Education and Research's J N Medical College

Ashalata Mallapur

S Nijalingappa Medical College and HSK Hospital & Research Centre

Umesh Charantimath

KLE Academy of Higher Education and Research's J N Medical College

Umesh Ramadurg

S Nijalingappa Medical College and HSK Hospital & Research Centre

Geetanjali Katageri

S Nijalingappa Medical College and HSK Hospital & Research Centre

Maria Lesperance

Richmond Division of Family Practice

Mai-Lei Woo Kinshella

University of British Columbia

Raiya Suleman

University of British Columbia

Sumedha Sharma

University of British Columbia

Marianne Vidler

University of British Columbia

Richard Derman

Thomas Jefferson University

Laura A Magee (✉ laura.a.magee@kcl.ac.uk)

King's College London

Peter von Dadelszen

King's College London

Research Article

Keywords: Anemia in pregnancy, hypertension, global health

Posted Date: January 27th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1232789/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Iron-deficiency anemia is a known risk factor for several adverse perinatal outcomes, but its impact on maternal morbidity is less certain. Further, data on associations between anemia in early pregnancy and subsequent outcomes are understudied.

Methods

The study population was derived from the Community Level Interventions for Pre-eclampsia (CLIP) trial in Karnataka State, India (NCT01911494). Included were women who were enrolled in either trial arm, delivered by trial end date, and had a baseline measure of hemoglobin (Hb). Anemia was classified by WHO standards into four groups: none ($\text{Hb} \geq 11 \text{ g/dL}$), mild ($10.0 \text{ g/dL} \leq \text{Hb} < 11.0 \text{ g/dL}$), moderate ($7.0 \text{ g/dL} \leq \text{Hb} < 10.0 \text{ g/dL}$) and severe ($\text{Hb} < 7.0 \text{ g/dL}$). Targeted maximum likelihood estimation was used to estimate confounder-adjusted associations between anemia and a composite (and its components) of adverse maternal outcomes, including pregnancy hypertension. E-values were calculated to assess robustness to unmeasured confounding.

Results

Of 11,370 women included, 10,066 (88.5%) had anemia, that was mild (3690, 32.5%), moderate (6023, 53.0%), or severe (68, 0.6%). Almost all women (>99%) reported taking iron supplements during pregnancy. Blood transfusions was more often administered to those with anemia that was mild (risk ratio [RR] 2.16, 95% confidence interval [CI] 1.31-3.56), moderate (RR 2.37, 95% CI 1.56-3.59), and severe (RR 5.70, 95% CI 3.00-10.85). No significant association was evident between anemia severity and haemorrhage (antepartum or postpartum) or sepsis, but there was a U-shaped association between anemia severity and pregnancy hypertension and pre-eclampsia specifically, with the lowest risk seen among those with mild or moderate anemia.

Conclusion

In Karnataka State, India, current management strategies for mild-moderate anemia in early pregnancy are associated with similar rates of adverse maternal or perinatal outcomes, and a lower risk of pregnancy hypertension and preeclampsia, compared with no anemia in early pregnancy. Future research should focus on risk mitigation for women with severe anemia, and the potential effect of iron supplementation for women with normal Hb in early pregnancy.

Funding

PRE-EMPT, a grant awarded to University of British Columbia by the Bill & Melinda Gates Foundation (# OPP1017337).

Introduction

Anemia in pregnancy is a global health concern with the burden falling on low- and middle-income countries (LMIC) in Africa and Southeast Asia, with rates more than twice as high as in high-income settings (1–4). Iron deficiency is the most common cause of anemia in pregnancy, other causes include deficiency of B12 or folic acid, thalassemias, intrinsic red blood cell disorders, bacterial and parasitic infections (1). In India specifically, although the prevalence of anemia during pregnancy has been decreasing as of 2018, rates remain unacceptably high (2,5).

Maternal anemia has well established connections with adverse neonatal outcomes such as low birth weight, small for gestational age and premature delivery (6–9). Further, recent evidence from diverse LMIC settings found maternal deaths to be nearly twice as high in individuals with severe anemia (10). There are also data linking anemia with pre-eclampsia, puerperal sepsis, ante-partum hemorrhage (APH), and post-partum hemorrhage (11–15). These studies have well-documented limitations, and important gaps remain in understanding the associations between severity of anemia and adverse maternal outcomes (10,16). Furthermore, although iron supplementation has been shown to have protective effects of maternal anemia (at delivery) and low birthweight, there is little evidence for its impact on other adverse pregnancy outcomes (17–19).

Using data from over 10,000 pregnancies in the Community Level Interventions for Pre-Eclampsia (CLIP) trial in Karnataka State, India (20) these analyses measure the prevalence of anemia and iron supplementation and assess the impact of anemia severity in early pregnancy on adverse maternal outcomes including need for blood transfusion, ante-partum hemorrhage, and hypertension.

Methods

This was an unplanned secondary analysis using data from the CLIP India trial (20) with the goal of estimating the effect of early pregnancy anemia on maternal and perinatal outcomes in a population with high rates of iron supplementation.

CLIP India Trial

The CLIP India trial was a prospective, cluster randomized control trial that took place in 12 clusters in Belagavi and Bagalkote districts, rural Karnataka. The units of randomization were primary health care centers and were chosen by the site teams based on a variety of feasibility and logistical considerations. Four clusters (two per arm) were included in a pilot phase from February 1st, 2014 to October 31st, 2014. These four clusters were then joined by the additional eight for a two-year definitive phase from November 1st, 2014 to October 31st, 2016.

Participants were married pregnant women (ages 15-49) who provided written informed consent for data collection. In both the intervention and control clusters, data was obtained via household and facility-based surveys. These surveys were conducted by community health care workers and research staff to

collect socio-demographic characteristics, care seeking behaviours, maternal outcomes and neonatal outcomes. Data was collected at three time points, (i) as soon as possible after enrolment after pregnancy confirmation (focus on obstetric and medical and previous pregnancy history), (ii) as soon as possible after delivery (focus on care seeking, delivery information and pregnancy outcome for current pregnancy), and (iii) within 42 days postpartum (confirmation and update of pregnancy outcome). Data collection was done through the Maternal and Newborn Health (MNH) registry system (21).

Women in the intervention clusters received additional 'CLIP visits' during both the antenatal and postnatal periods. These visits were conducted by community health care workers and were guided by the PIERS on the Move (POM) mobile health technology risk stratification tool (22). The intervention clusters also had community engagement sessions for women and other community members to promote knowledge about risks and symptoms of pregnancy hypertension.

Inclusion and exclusion criteria

The inclusion criteria for the analyses were women who had delivered by the end of the trial (October 31st, 2016) with a hemoglobin measurement at trial enrolment.

Exposure, outcomes and confounders

Hemoglobin level was collected at trial enrolment, which for the majority of women was during the first trimester. Hemoglobin was assessed using Sahli's method. Maternal anemia was defined as hemoglobin (Hb) < 11 g/dl and severity was further subdivided based on World Health Organization (WHO) standards into: mild ($10.0\text{g/dL} \leq \text{Hb} < 11.0\text{ g/dL}$), moderate ($7.0\text{g/dL} \leq \text{Hb} < 10.0\text{ g/dL}$) and severe ($\text{Hb} < 7.0\text{ g/dL}$).

We analyzed several maternal outcomes. First, we looked at those that have been commonly associated with anemia, including blood transfusion, antepartum hemorrhage, maternal sepsis, and postpartum hemorrhage. Outcomes were self-reported and clinically adjudicated for accuracy as part of the CLIP trial (20). The only exception was postpartum hemorrhage which was collected within the MNH registry. Second, we assessed pregnancy hypertension (defined as systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90). Blood pressure data were only available on women in the intervention arm, so analyses of hypertension were restricted to this group. Data were collected during POM visits using standardised methods and a semi-automated, pregnancy-validated digital device (Microlife BP 3AS1-2) (23). In addition to defining hypertension based strictly from POM measurements, we also used a previously published definition (for this data) to combine information from POM and hypertension reported in trial surveillance data sources to assess an expanded version of hypertension, as well as pre-eclampsia (24). Pre-eclampsia was defined as gestational hypertension with proteinuria or 1 or more relevant end-organ complications (24).

Secondary outcomes included severe perinatal outcomes including perinatal death, stillbirth, early and late neonatal death, neonatal morbidity, and a composite of these outcomes.

Possible confounders were identified based on expert knowledge and possible relationship between anemia and adverse outcomes (25). These include: trial arm, cluster, maternal age, nulliparity, body-mass-index (measured at enrolment), maternal and husband basic education, gestational age at booking, religion (as a possible proxy for vegetarian diet), and twin pregnancy.

Information on iron supplementation was only collected postpartum, and timing of initiation was not ascertained. We did not adjust for iron supplementation as it occurred after exposure and therefore may be on the causal pathway between exposure and outcome. Furthermore, almost all women (>99%) who delivered reported taking supplementation, but timing and adherence were not available.

Statistical analysis

The rate of women with no, mild, moderate, and severe anemia were estimated. Demographic and clinical outcomes were stratified across anemic groups and summarized as counts and percentages for categorical variables and medians and IQR for continuous variables. For each anemic group, iron supplementation rates were compared between women with miscarriages and MTP and those whose pregnancies ended in live or stillbirth. Women with medically terminated pregnancies or miscarriages were excluded from analysis of maternal and perinatal outcomes.

We used Targeted Maximum Likelihood Estimation (TMLE) to estimate risk ratios and differences between non-anemic women and women with mild and moderate anemia on our primary outcomes of interest (26). TMLE has the advantage over traditional regression (e.g., logistic) models in that it combines a propensity score model for the exposure (anemia) and a model for the outcome and if either of these models is correctly specified the estimate of association is unbiased; this is known as a doubly robust estimator (27). Further, TMLE allows one to use nonparametric algorithms which do not make modeling assumptions (e.g., linearity, no interaction etc.) that are common in standard regression models. In these analyses we used an ensemble (i.e., 'stacking') of prediction algorithms. These included standard regression models both with and without interactions, generalized additive models, mean outcome models and tree-based algorithms. These were used in both the exposure and outcome models. All results are presented with 95% confidence intervals estimated via the delta method and were adjusted for the clustered nature of the data via previously published methods (28).

To assess possible dose-response relationship between hemoglobin level and adverse outcomes we included baseline hemoglobin as a continuous variable in mixed effects logistic regression models to estimate adjusted (for all above confounders) dose-response curves. We used restricted cubic splines with 3 degrees of freedom to allow for non-linearity in the hemoglobin/outcome relationship and plotted marginal risk curves for each outcome. Due to software limitations, TMLE is not available for continuous exposures.

We used E-values to assess the strength of an unmeasured confounder (such as dietary or nutritional intake) between baseline hemoglobin and adverse outcomes (on the risk ratio scale) that would be

needed to explain away our results (29). These were applied to all points estimates and lower bounds of the 95% confidence intervals when these values were >1.0.

All perinatal outcomes were analyzed similarly to the above. All data analysis was conducted using R statistical software version 4.0.3 (30) TMLE was conducted using the *drtmle* package.

Results

A total of 14,783 pregnancies were enrolled in the trial. Of these, 13,017 (88.1%) had completed pregnancies within the trial period, and 11,370 delivered, while 1013 miscarried and 629 had a medically terminated pregnancy and 5 had unknown status. Among those who delivered, 11,085 had a baseline hemoglobin value; 10,066 (88.5%) were anemic at enrolment with the majority having moderate anemia (n=6023, 59.8%) and only 68 (0.6%) having severe anemia. The distribution of hemoglobin levels was roughly bell-shaped, with observations mostly clustered between 8-12 g/dL (Figure 1).

The majority of baseline characteristics were similar between those with varying levels of anemia. The only exceptions were parity and basic education (both maternal and husband), where anemic women were more likely to be parous and households with no anemia were more educated. Gestational age at delivery was similar in all groups (median of 39 weeks). There were decreasing rates of caesarean section with increasing anemia severity. Almost all (>99%) delivered women were taking iron supplementation at time of delivery (Table 1). Women who miscarried or had medically terminated pregnancies had low rates of supplementation (25%, Table S2).

Maternal morbidity occurred in roughly 5% of included pregnancies and rates were increased in all anemic groups. The three most common morbidities were blood transfusion, APH and sepsis; other morbidities were rare. There were nine maternal deaths (5 in mildly anemic and 4 in moderately anemic). Most women in the intervention arm had blood pressure measurements and this was consistent across levels of anemia severity. Hypertension was documented in around 10% of pregnancies and was highest in women without anemia. Postpartum hemorrhage was documented in less than 1% of pregnancies (Table 2).

The confounder adjusted association between early pregnancy anemia and adverse outcomes is provided in Table 3. For blood transfusion, there was increasing risk on both additive and multiplicative scales in all anemic groups compared to those with normal hemoglobin levels at baseline. There were no observed differences in either APH or sepsis, but confidence intervals were wide and consistent with both large increases and decreases in risk between groups. Results for postpartum hemorrhage were inconclusive in mild and moderately anemic women. Severely anemic women showed increased risk, but this estimate was based on only 2 events. Hypertension by both definitions was lower (compared to non-anemic) by between 20-25% in mild and moderately anemic women, respectively; comparisons for severely anemic women for hypertension defined by POM had wide confidence intervals and were uncertain. For the expanded definition, women with severe anemia had lower risk than those with no anemia. Risk of pre-eclampsia was reduced in mild and moderately anemic women by about 30% and

was 37% higher in severely anemic women. For each of hypertension and pre-eclampsia, estimates for severely anemic women were based on only 3 events.

An unmeasured confounder beyond those included in our models would need to increase the risk of anemia and hypertension by a minimum of 60-90% on the risk ratio scale to explain away the observed associations (E-values for lower confidence bounds, Table 3).

Dose-response relationships between hemoglobin and risk showed roughly linear increasing rates of the composite primary outcome with decreasing hemoglobin; however, confidence intervals at lower hemoglobin values were wide due to few measurements. Blood transfusion followed a similar pattern, while sepsis, APH and PPH estimated risks were relatively flat. There was a U-shaped relationship between hemoglobin level and hypertension (both definitions) and pre-eclampsia (Figure 2). The inflection points for each of these outcomes was 10g/dL. Estimated risks at each unit g/dL for each outcome are available in Table S3.

Adverse perinatal outcomes occurred in 20% of pregnancies with no anemia, 17% of pregnancies with mild or moderate anemia, and 29% of severely anemic pregnancies. Adjusted analyses for the relationship between anemia and perinatal death, stillbirth, early and late neonatal death and neonatal morbidity showed no consistent association as confidence intervals were too wide to draw meaningful inference (Table S4). Dose response curves for perinatal outcomes showed higher risk at very low hemoglobin values for all outcomes. For the composite perinatal outcome rates were flat for mild/moderate levels of anemia and declined for higher hemoglobin values; this was driven by neonatal morbidity as curves for perinatal death, stillbirth, and early and late neonatal deaths were mostly flat (Figure 2 and S1).

Discussion

Summary of findings

Most women in the CLIP India trial had some form of anemia at the time of antenatal care booking, most commonly moderate and rarely, severe. Almost all women received iron supplementation by the time of delivery, regardless of baseline anemia, and in line with Indian guidelines for routine supplementation. In addition, just under 5% received blood transfusion, which was a greater number than those who experienced antepartum or postpartum bleeding,

Compared with a normal hemoglobin level, each of mild, moderate, and severe anemia more frequently prompted receipt of maternal blood transfusion. Women with mild-moderate anemia had no excess of adverse pregnancy outcomes, including bleeding and sepsis, although women with severe anemia was associated with an increased risk of PPH. The findings were unlikely to be related to unmeasured confounders, particularly for severe anemia. However, we observed a 'U-shaped' relationship between anemia severity and pregnancy hypertension, and pre-eclampsia specifically, with women with mild- or moderate anemia having significantly lower rates.

Given the near 100% reported rate of iron supplementation in delivered women in this cohort, these data represent the estimated effect of early pregnancy anemia on outcomes in a population where public health efforts for supplementation in pregnancy have been successful.

Comparison with the literature

The prevalence of anemia in pregnancy in India is amongst the highest in the world. Estimates have varied from a substantial proportion to most women in pregnancy, as in our study. In South India, Vindhya *et al.* estimated the prevalence of anemia in pregnant women to be 33.9%, with 48.4% of cases being mild, 49.5% moderate, and 2.1% severe(5). Other studies have reported even higher rates of maternal anemia in India, up to 88%, similar to our study(2,5) that demonstrate higher than previously published data from Belgaum and Bagalkote (31).

Major factors contributing to the prevalence of anemia in India are low dietary intake of both iron and folic acid, poor bioavailability of iron (3-4% only) in phytate, and chronic blood loss from infections, such as malaria and hookworm(32). Of note, <1% of our study population had malaria. We did not have data to explore possible dietary mechanisms.

Many studies in India and elsewhere have examined the impact of maternal anemia on perinatal outcomes, such as stillbirth, low birth weight, small for gestational age, and preterm birth (8,9,33–36). Far fewer studies have examined the impact of maternal anemia on maternal outcomes, even by systematic review of LMIC data (6,15). One recent review found a 190% increase in the odds of blood transfusion in anemic women (37), but they did not stratify by severity of anemia, as in our study.

The relationship between anemia and anemia severity on gestational hypertension and pre-eclampsia has been mixed. A large cohort study from India and Pakistan (110,033 anemic women) found a U-shaped relationship in Indian women (RRs = 1.89 95% CI = 1.12 to 3.18) for severe anemia, but ~1.0 for mild/moderate) but not in Pakistani women (RR = 1.18, 95% CI = 0.81 to 1.73 for severe anemia) (15). Another smaller study case-control from Sudan (606 anemic women) found increases in pre-eclampsia severe anemia (OR = 3.6, 95% CI = 1.4 to 9.1) , as well as possible increases with mild or moderate (OR = 1.60, 95% CI = 0.80 to 3.40) (38). In contrast, Jung *et al.*'s review of nine studies found little difference in pre-eclampsia among anemic women (OR = 1.15 95% CI = 0.80 to 1.64); however, they did observe a U-shaped dose-response relationship (37) similar to ours and to the Indian cohort referenced above (15). Mechanisms for the relationship between higher hemoglobin values and pregnancy hypertension may include poor nutrient supply to the placenta due to increased blood thixotropy, and production of reactive oxygen species, together with increased iron (39).

It is clear that iron supplementation can increase hemoglobin values in pregnancy, but effectiveness is challenged by poor adherence, continuous access to iron tablets, use of doses lower than necessary, and oral (vs. parenteral) route of administration (32,40,41). However, even when effective, the impact of anemia treatment on adverse maternal and perinatal outcomes remains uncertain. The most recent Cochrane review found that few studies have assessed the impact of iron supplementation on APH,

blood transfusion, sepsis, or pre-eclampsia, and most did not focus on anemia in early pregnancy (18). Our findings suggest that current management strategies for mild and moderate anemia are largely effective in reducing risk to that comparable to women with normal hemoglobin. However, more research is needed to understand the increased risk of hypertensive pregnancy in those with normal hemoglobin, and whether iron supplementation is related.

Strengths and limitations

Our study has several strengths, including our large prospective cohort, standardized collection of blood pressure data using a device validated for use in pregnancy and pre-eclampsia, and detailed documentation of other pregnancy outcomes and possible confounders of the anemia-outcome relationship in a high-quality cluster randomized trial. Also, we report findings in the context of successful public health efforts to provide iron supplementation to all pregnant women in India, where malaria is not endemic.

Our study has some limitations. First, our sample size of severely anemic women was small, and therefore despite the large effect sizes, caution should be taken in the extrapolation of findings related to this group, as they may be subject to sparse data bias. Conversely, just over 11% of women had normal hemoglobin, and few had a hemoglobin above 15g/dL to fully evaluate the U-shaped relationship between anemia and pregnancy hypertension. Second, we lacked data on the exact timing of initiation of iron supplementation and associated adherence; stratification by such information may have provided further nuance to our findings. We found low rates of supplementation in miscarried or MTP pregnancies, which occur (by definition) before 20 weeks. Therefore, it is possible that most women began supplementation after this point. Third, we had no information on the reasons for transfusion, but in all groups, the number of women transfused exceeded those with clinical bleeding. Fourth, this is a secondary analysis of data from a clinical trial with different primary objectives, so we did not measure hemoglobin levels throughout pregnancy, or collect information about potential dietary mechanisms. Although we did adjust for vegetarian diet, there are risks of residual confounding due to unmeasured differences (such as diet and nutrition) between anemic and non-anemic women. Our E-values indicate that such variables would need to have strong effect above and beyond our adjustment to explain away the increased risk for severe anemia. For moderate and mild anemia's relationship with hypertension, E-values were more moderate (1.5-2.0), but still unlikely to explain away the U-shape. Finally, as all participants were prescribed iron supplementation, so we cannot comment on the relative benefits and risks of iron supplementation vs. no supplementation.

Conclusion

In a cohort of women with habitual anemia, who reported routine iron supplementation and infrequent blood transfusion during pregnancy, mild-moderate anemia in early pregnancy (compared with normal Hb) is associated with similar pregnancy outcomes, but lower rates of pregnancy hypertension and pre-eclampsia. These findings suggest that new strategies should be developed for women with severe

anemia in early pregnancy. Furthermore, routine iron supplementation for women with normal Hb in early pregnancy needs further exploration due to increased hypertension in a population with widely prevalent anemia.

Declarations

Ethics approval and consent to participate

Ethical approval for the trials and individual participant-level data meta-analysis was granted by the University of British Columbia, Vancouver, BC, Canada (H12-03497) and in India at the from, MDC/IECHSR/2011-12/A-4, ICMR 5/7/859/12-RHN; All eligible pregnant women provided written informed consent to participate. All trial methods was conducted in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and final responsibility for the decision to submit for publication.

Availability of data and materials

The datasets used and/or analysed during the current study are not publicly available as the low outcomes rates of some outcomes may allow for identification and be a breach of confidentiality but are available from the corresponding author on reasonable request.

Competing interests

LAM and PvD report grants from the Bill & Melinda Gates Foundation, during the conduct of the study. All other authors declare no competing interests.

Funding

PRE-EMPT, a grant awarded to University of British Columbia by the Bill & Melinda Gates Foundation (# OPP1017337).

Author's contributions

JB, ML, MV, SS, LM and PvD planned the secondary study. PvD designed the concept of the CLIP trials. LM, MB, and SG were co-principal investigators. JB conducted the statistical analyses and wrote the first

draft of the manuscript with help from ML, GK and LM. All authors read and approved the final version of the manuscript.

Acknowledgments

We thank the Government of India for their permission to integrate the CLIP trial into their health systems with in-kind support and the entire CLIP India trialw

References

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. *Public Health Nutr.* 2009 Apr;12(4):444–54.
2. Lee AI, Okam MM. Anemia in Pregnancy. *Hematol Oncol Clin North Am.* 2011 Apr 1;25(2):241–59.
3. Balarajan Y, Ramakrishnan U, Özaltin E, Shankar AH, Subramanian SV. Anaemia in low-income and middle-income countries. *The Lancet.* 2011 Dec 17;378(9809):2123–35.
4. Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: a systematic analysis of population-representative data. *Lancet Glob Health.* 2013 Jul 1;1(1):e16–25.
5. Kalaivani K, Ramachandran P. Time trends in prevalence of anaemia in pregnancy. *Indian J Med Res.* 2018 Jan 3;147(3):268.
6. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, et al. Maternal anemia and risk of adverse birth and health outcomes in low- and middle-income countries: systematic review and meta-analysis1,2. *Am J Clin Nutr.* 2016 Feb 1;103(2):495–504.
7. Rahmati S, Delpishe A, Azami M, Hafezi Ahmadi MR, Sayehmiri K. Maternal Anemia during pregnancy and infant low birth weight: A systematic review and Meta-analysis. *Int J Reprod Biomed.* 2017 Mar;15(3):125–34.
8. Figueiredo ACMG, Gomes-Filho IS, Silva RB, Pereira PPS, Mata FAFD, Lyrio AO, et al. Maternal Anemia and Low Birth Weight: A Systematic Review and Meta-Analysis. *Nutrients.* 2018 May 12;10(5).
9. Jessani S, Saleem S, Hoffman MK, Goudar SS, Derman RJ, Moore JL, et al. Association of haemoglobin levels in the first trimester and at 26–30 weeks with fetal and neonatal outcomes: a secondary analysis of the Global Network for Women’s and Children’s Health’s ASPIRIN Trial. *BJOG Int J Obstet Gynaecol* [Internet]. [cited 2021 May 20];n/a(n/a). Available from: <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/1471-0528.16676>
10. Daru J, Zamora J, Fernández-Félix BM, Vogel J, Oladapo OT, Morisaki N, et al. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. *Lancet Glob Health.* 2018 May 1;6(5):e548–54.

11. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health*. 2014 Jun;2(6):e323-333.
12. Severe Maternal Sepsis in the UK, 2011–2012: A National Case-Control Study [Internet]. [cited 2021 Apr 12]. Available from: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001672>
13. Rukuni R, Bhattacharya S, Murphy MF, Roberts D, Stanworth SJ, Knight M. Maternal and neonatal outcomes of antenatal anemia in a Scottish population: a retrospective cohort study. *Acta Obstet Gynecol Scand*. 2016 May;95(5):555–64.
14. Kassa GM, Muche AA, Berhe AK, Fekadu GA. Prevalence and determinants of anemia among pregnant women in Ethiopia; a systematic review and meta-analysis. *BMC Hematol* [Internet]. 2017 Oct 17 [cited 2021 Apr 8];17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646153/>
15. Ali SA, Tikmani SS, Saleem S, Patel AB, Hibberd PL, Goudar SS, et al. Hemoglobin concentrations and adverse birth outcomes in South Asian pregnant women: findings from a prospective Maternal and Neonatal Health Registry. *Reprod Health*. 2020 Nov 30;17(Suppl 2):154.
16. Rath WH. Postpartum hemorrhage—update on problems of definitions and diagnosis. *Acta Obstet Gynecol Scand*. 2011 May;90(5):421–8.
17. Imdad A, Bhutta ZA. Routine iron/folate supplementation during pregnancy: effect on maternal anaemia and birth outcomes. *Paediatr Perinat Epidemiol*. 2012 Jul;26 Suppl 1:168–77.
18. Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. *Cochrane Database Syst Rev*. 2015 Jul 22;(7):CD004736.
19. Zhao G, Xu G, Zhou M, Jiang Y, Richards B, Clark KM, et al. Prenatal Iron Supplementation Reduces Maternal Anemia, Iron Deficiency, and Iron Deficiency Anemia in a Randomized Clinical Trial in Rural China, but Iron Deficiency Remains Widespread in Mothers and Neonates123. *J Nutr*. 2015 Aug;145(8):1916–23.
20. Bellad MB, Goudar SS, Mallapur AA, Sharma S, Bone J, Charantimath US, et al. Community level interventions for pre-eclampsia (CLIP) in India: A cluster randomised controlled trial. *Pregnancy Hypertens*. 2020 Jul 1;21:166–75.
21. Goudar SS, Stolka KB, Koso-Thomas M, Honnungar NV, Mastiholi SC, Ramadurg UY, et al. Data quality monitoring and performance metrics of a prospective, population-based observational study of maternal and newborn health in low resource settings. *Reprod Health*. 2015 Jun 8;12(2):S2.
22. Payne BA, Hutcheon JA, Ansermino JM, Hall DR, Bhutta ZA, Bhutta SZ, et al. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. *PLoS Med*. 2014 Jan;11(1):e1001589.
23. Nathan HL, de Greeff A, Hezelgrave NL, Chappell LC, Shennan AH. An accurate semiautomated oscillometric blood pressure device for use in pregnancy (including pre-eclampsia) in a low-income

- and middle-income country population: the Microlife 3AS1-2. *Blood Press Monit.* 2015 Feb;20(1):52–5.
24. Magee LA, Sharma S, Nathan HL, Adetoro OO, Bellad MB, Goudar S, et al. The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. *PLOS Med.* 2019 Apr 12;16(4):e1002783.
 25. Greenland S, Pearce N. Statistical Foundations for Model-Based Adjustments. *Annu Rev Public Health.* 2015;36(1):89–108.
 26. Laan MJ van der, Rose S. Targeted Learning: Causal Inference for Observational and Experimental Data. Springer Science & Business Media; 2011. 678 p.
 27. Benkeser D, Carone M, Laan MJVD, Gilbert PB. Doubly robust nonparametric inference on the average treatment effect. *Biometrika.* 2017 Dec;104(4):863–80.
 28. Schnitzer ME, van der Laan MJ, Moodie EEM, Platt RW. EFFECT OF BREASTFEEDING ON GASTROINTESTINAL INFECTION IN INFANTS: A TARGETED MAXIMUM LIKELIHOOD APPROACH FOR CLUSTERED LONGITUDINAL DATA. *Ann Appl Stat.* 2014 Jun;8(2):703–25.
 29. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med.* 2017 Jul 11;167(4):268–74.
 30. R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing [Internet]. Vienna, Austria.; Available from: URL <https://www.R-project.org/>
 31. District-wise Key Indicators of NFHS-4 for Karnataka [Internet]. Open Government Data (OGD) Platform India. 2017 [cited 2021 Apr 8]. Available from: <https://data.gov.in/resources/district-wise-key-indicators-nfhs-4-karnataka>
 32. Agarwal KN, Agarwal DK, Sharma A, Sharma K, Prasad K, Kalita MC, et al. Prevalence of anaemia in pregnant & lactating women in India. *Indian J Med Res.* 2006 Aug;124(2):173–84.
 33. Patel A, Prakash AA, Das PK, Gupta S, Pusdekar YV, Hibberd PL. Maternal anemia and underweight as determinants of pregnancy outcomes: cohort study in eastern rural Maharashtra, India. *BMJ Open.* 2018 Aug 8;8(8):e021623.
 34. Finkelstein JL, Kurpad AV, Bose B, Thomas T, Srinivasan K, Duggan C. Anaemia and iron deficiency in pregnancy and adverse perinatal outcomes in Southern India. *Eur J Clin Nutr.* 2020 Jan;74(1):112–25.
 35. Allen LH. Anemia and iron deficiency: effects on pregnancy outcome. *Am J Clin Nutr.* 2000 May 1;71(5):1280S-1284S.
 36. Nair M, Churchill D, Robinson S, Nelson-Piercy C, Stanworth SJ, Knight M. Association between maternal haemoglobin and stillbirth: a cohort study among a multi-ethnic population in England. *Br J Haematol.* 2017;179(5):829–37.
 37. Jung J, Rahman MM, Rahman MS, Swe KT, Islam MR, Rahman MO, et al. Effects of hemoglobin levels during pregnancy on adverse maternal and infant outcomes: a systematic review and meta-analysis. *Ann N Y Acad Sci.* 2019;1450(1):69–82.

38. Ali AA, Rayis DA, Abdallah TM, Elbashir MI, Adam I. Severe anaemia is associated with a higher risk for preeclampsia and poor perinatal outcomes in Kassala hospital, eastern Sudan. BMC Res Notes. 2011 Aug 26;4:311.

39. Dewey KG, Oaks BM. U-shaped curve for risk associated with maternal hemoglobin, iron status, or iron supplementation. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1694S-1702S.

40. Ahamed F, Yadav K, Kant S, Saxena R, Bairwa M, Pandav CS. Effect of directly observed oral iron supplementation during pregnancy on iron status in a rural population in Haryana: A randomized controlled trial. Indian J Public Health. 2018 Dec;62(4):287–93.

41. Sajith M, Nimbargi V, Shah S, Tekawade S, Agiwale J, Pawar A. Correlations of adherence to iron supplements and prevalence of anemia in antenatal women. Int J Reprod Contracept Obstet Gynecol. 2016 Dec 15;5(10):3448–52.

Tables

Table 1: Demographics and pregnancy characteristics by anemia level

	None (N = 1304)	Mild (N = 3690)	Moderate (N = 6023)	Severe (N = 68)
Maternal age	22.00 [20.00, 24.00]	22.00 [20.00, 25.00]	23.00 [20.00, 25.00]	23.00 [21.00, 26.00]
Parous	710 (54.5)	2306 (62.5)	3983 (66.1)	48 (70.6)
Maternal basic education	868 (66.6)	2197 (59.5)	3117 (51.8)	31 (45.6)
Husband basic education	884 (67.8)	2299 (62.3)	3362 (55.8)	37 (54.4)
Multiple pregnancy	12 (0.9)	35 (0.9)	49 (0.8)	1 (1.5)
Body-mass-index	19.95 [18.08, 22.20]	19.57 [17.80, 21.58]	19.11 [17.54, 21.00]	18.73 [17.34, 20.39]
Iron supplementation*	1290 (98.9)	3662 (99.2)	5969 (99.1)	68 (100.0)
Religion				
Hindu	1188 (91.1)	3335 (90.4)	5569 (92.5)	63 (92.6)
Muslim	109 (8.4)	336 (9.1)	423 (7.0)	5 (7.4)
Other	7 (0.5)	19 (0.5)	31 (0.5)	0 (0.0)
Gestational age at enrolment	11.14 [8.00, 15.86]	11.43 [8.43, 15.57]	11.57 [8.71, 16.00]	13.57 [9.57, 18.57]
Gestational age at delivery	39.00 [38.00, 40.00]	39.00 [38.00, 40.00]	39.00 [38.00, 40.00]	39.00 [36.75, 40.00]
Mode of delivery				
Vaginal	933 (71.5)	2760 (74.8)	4748 (78.8)	56 (82.4)
Vaginal (assisted)	12 (0.9)	40 (1.1)	51 (0.8)	1 (1.5)
Caesarian section	359 (27.5)	890 (24.1)	1224 (20.3)	11 (16.2)
Trial arm				
Intervention	705 (54.1)	2247 (60.1)	2814 (46.7)	32 (47.1)
Control	599 (45.9)	1443 (39.1)	3209 (53.3)	36 (52.9)
Blood pressure measurement from POM	644 (49.4)	2032 (55.1)	2592 (43.0)	27 (39.7)

*Asked at time of delivery

Table 2: Maternal mortality and morbidity by anemia level

	None (N = 1304)	Mild (N = 3690)	Moderate (N = 6023)	Severe (N = 68)
Maternal mortality	0 (0%)	5 (0.1%)	4 (0.1%)	0 (0%)
Blood transfusion	32 (2.5%)	151 (4.1%)	269 (4.5%)	8 (11.8%)
Antepartum hemorrhage	13 (1.0%)	47 (1.3%)	39 (0.6%)	1 (1.5%)
Sepsis	14 (1.1%)	46 (1.2%)	65 (1.1%)	0 (0%)
Postpartum hemorrhage	8 (0.6%)	25 (0.7%)	42 (0.7%)	2 (2.9%)
Hypertension (POM)*	80 (12.4%)	186 (9.2%)	223 (8.6%)	3 (11.1%)
Hypertension (expanded)*	136 (21.0%)	318 (15.6%)	378 (14.5%)	3 (11.1%)
Pre-eclampsia*	57 (8.8%)	130 (6.4%)	157 (6.0%)	3 (11.1%)

*Only available in women in intervention arm with antepartum blood pressure measurements and not included in composite outcomes

Table 3: Adjusted risk ratios and differences between women with no anemia and those with mild, moderate and severe.

	Unadjusted risk (%)	Risk difference % (95% CI)*	Risk ratio (95% CI)*	E-value point estimate**	E-value lower bound**
Blood transfusion					
None	2.5	Reference	Reference	-	-
Mild	4.1	2.27 (1.29, 3.26)	2.16 (1.31, 3.56)	3.74	1.95
Moderate	4.5	2.68 (1.77, 3.58)	2.37 (1.56, 3.59)	4.17	2.50
Severe	11.8	9.20 (3.18, 15.23)	5.70 (3.00, 10.85)	10.9	5.45
Antepartum hemorrhage					
None	1.0	Reference	Reference	-	-
Mild	1.3	0.22 (-0.54, 0.97)	1.20 (0.63, 2.29)	-	-
Moderate	0.6	-0.39 (-1.14, 0.36)	0.65 (0.30, 1.39)	-	-
Severe	1.5	NA***	NA***	-	-
Sepsis					
None	1.1	Reference	Reference	-	-
Mild	1.2	0.01 (-0.69, 0.70)	1.01 (0.62, 1.65)	-	-
Moderate	1.1	-0.23 (-1.27, 0.82)	0.84 (0.36, 1.94)	-	-
Severe	0.0	NA***	NA***	-	-
Postpartum hemorrhage					
None	0.6	Reference	Reference	-	-
Mild	0.7	0.15 (-0.23, 0.54)	1.34 (0.60, 3.00)	-	-
Moderate	0.7	0.24 (-0.13, 0.61)	1.53 (0.69, 3.40)	-	-
Severe	2.9	1.72 (-0.89, 4.33)	4.82 (1.27, 18.3)	9.11	1.86
Hypertension (POM)****					

None	12.4	Reference	Reference	-	-
Mild	9.2	-3.11 (-4.15, -2.07)	0.75 (0.70, 0.80)	2.00	1.80
Moderate	8.6	-3.62 (-5.84, -1.39)	0.70 (0.58, 0.85)	2.21	1.63
Severe	11.1	0.01 (-7.12, 7.13)	1.00 (0.56, 1.79)	-	-
Hypertension (expanded)****					
None	21.0	Reference	Reference	-	-
Mild	15.6	-3.79 (-5.48, -2.1)	0.80 (0.73, 0.88)	1.80	1.53
Moderate	14.5	-4.35 (-6.24, -2.47)	0.77 (0.70, 0.85)		1.63
Severe	11.1	-7.72 (-13.77, -1.66)	0.60 (0.34, 1.05)	-	-
Pre-eclampsia****					
None	8.8	Reference	Reference	-	-
Mild	6.4	-2.13 (-5.14, 0.89)	0.75 (0.53, 1.07)	-	-
Moderate	6.0	-2.67 (-4.98, -0.35)	0.69 (0.55, 0.86)	2.25	1.60
Severe	11.1	3.20 (-1.23, 7.63)	1.37 (1.01, 1.88)	2.08	1.11
Perinatal composite					
None	19.9	Reference	Reference	-	-
Mild	17.5	-3.56 (-8.19, 1.07)	0.82 (0.65, 1.04)	-	-
Moderate	16.6	-2.94 (-7.38, 1.49)	0.85 (0.68, 1.07)	-	-
Severe	29.4	7.51 (-3.37, 18.39)	1.37 (0.89, 2.11)	-	-

*Estimates are adjusted for trial arm, maternal age, nulliparity, body-mass-index, gestational age at enrolment, maternal basic education, husband basic education, multiple pregnancy, and religion.

**Size of association between unmeasured confounder and outcome needed to move the point estimate or lower bound of confidence interval to 1.0 (i.e., compatible with a null effect). Only displayed for those estimates where the lower confidence bound is > 1 .

***Could not be reliably estimated due to small sample size.

****Only available for women in the intervention arm with blood pressure measurement.

Figures

Figure 1

Distribution of baseline hemoglobin levels. Red dashed lines indicate cut-offs for (left to right) severe, moderate and mild anemia.

Figure 2

Estimated dose-response curves between hemoglobin level and maternal outcomes. Dashed lines represent 95% confidence intervals. Risk is adjusted for trial arm, maternal age, nulliparity, body-mass-index, gestational age at enrolment, maternal basic education, husband basic education, multiple pregnancy and religion.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AppendixBMC.docx](#)